An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

Trial Profile

An Open-Label, Intrapatient Dose-Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Biological Activity of ATYR1940 in Patients With Early Onset and Other Pediatric Onset Facioscapulohumeral Muscular Dystrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2017

At a glance

  • Drugs ATYR 1940 (Primary)
  • Indications Facioscapulohumeral muscular dystrophy
  • Focus Adverse reactions
  • Sponsors aTyr Pharma
  • Most Recent Events

    • 14 Nov 2017 According to an aTyr Pharma media release, in october data was presented at the 22nd International Annual Congress of the World Muscle Society.
    • 27 Sep 2017 Results presented in an aTyr Pharma Media Release.
    • 27 Sep 2017 According to an aTyr Pharma media release, data will be presented in the upcoming 22nd International Annual Congress of the World Muscle Society 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top